secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001104659-25-114660
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics appoints Christopher Martin to Board of Directors
-----------------------------------------------------------------------

- Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.
- Appointment effective November 19, 2025; term expires at 2028 annual meeting.
- Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).
- Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/0001104659-25-114660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/tm2531112d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-114660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer